Physician profile
Prageet Kumar
NPI 1821417981
$4,280.87
in general payments reported to CMS, 2019-2025
16 companies · $289 in 2025
The $289 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $559 · 2020: $200 · 2021: $836 · 2022: $994 · 2023: $1,114 · 2024: $289 · 2025: $289.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,692.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,691.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $1,090.03 | 2019-2023 | Xarelto |
| Pfizer INC. | $391.73 | 2019-2024 | |
| Abbvie INC. | $370.35 | 2022-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $337.01 | 2019-2024 | Jardiance |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $318.86 | 2022-2024 | Caplyta |
| Novartis Pharmaceuticals Corporation | $299.36 | 2021-2023 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $260.43 | 2021-2025 | Lifevest |
| Teva Pharmaceuticals USA, INC. | $226.35 | 2023-2024 | Uzedy, Austedo Xr |
| Astrazeneca Pharmaceuticals Lp | $191.34 | 2019-2023 | Farxiga |
| Viatris Specialty LLC | $124.99 | 2025 | Yupelri |
| Otsuka America Pharmaceutical, INC. | $124.99 | 2023 | Rexulti |
| Vanda Pharmaceuticals INC. | $120.74 | 2025 | Fanapt |
| Neurocrine Biosciences, INC. | $119.90 | 2022 | |
| Merck Sharp & Dohme LLC | $114.42 | 2019-2023 | Verquvo, Zerbaxa, Dificid |
| Axsome Therapeutics, INC. | $112.28 | 2023 | Auvelity |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $78.09 | 2021-2025 | Veklury |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Prageet Kumar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.